You probably remember the first time a doctor talked to you about a genetic test for cancer. Maybe a sister or an aunt had been through it, and you wanted to know your own risk. For many, the result was simple relief, and the test slipped from mind.
That old relief is now being revisited. The Food and Drug Administration granted breakthrough device designation to a new multi-cancer blood test from Natera on October 9, 2026, OncLive reported.
The move landed as doctors are urging women screened years ago to ask whether their old results would still look the same today.
The reason is simple. The first wave of cancer gene tests, rolled out in the 1990s and 2000s, mostly looked for a small set of BRCA1 and BRCA2 mutations. Modern panels sequence dozens of genes at once, so variants that used to fall outside the test can now be flagged.
Also read: Scientists warn: Your vitamin D levels may already be dropping
In practice that means names most people have never heard. Genes like PALB2, ATM, CHEK2 and the Lynch syndrome genes all carry their own cancer risk, and none were on the old BRCA-only tests. A newer panel scans all of them in a single sample.
How much does that change the picture? A 2015 study of 966 at-risk patients, published in Annals of Surgical Oncology, scanned a wider set of genes than BRCA alone.
An extra 3.9 percent carried a harmful mutation the older test would have missed. The variants that showed up most often were in CHEK2, PALB2 and ATM.
Who should think about asking for a retest
Not everyone needs to go back to the clinic. The group doctors point to is specific. It is people who had a BRCA-only test more than five to seven years ago, with a family history of breast, ovarian or colon cancer.
Also read: Better blood pressure treatment could prevent half a million heart deaths a year
A new diagnosis in a close relative since the first test is another strong reason to revisit.
Older age at the first test matters too. Tests done before about 2015 generally covered fewer genes. A negative from that era does not carry the same weight as a negative from a modern panel.
A conversation with your own doctor or a genetic counselor is the right first step. They can look at the family history, the original test, and decide whether an expanded panel adds anything new.
What the Natera designation does and does not do
Natera's multi-cancer early detection assay is a blood test. It reads cell-free DNA, the small fragments of genetic material that leak into the bloodstream from tumors.
Also read: For adults over 70, only one type of exercise cuts fat without shrinking muscle
It is not a replacement for a hereditary cancer gene panel. It looks for signs that a cancer may already be growing, rather than for inherited risk.
Alexey Aleshin, chief medical officer at Natera, said the designation "underscores the rigor and promise of our MCED program." He added that the company looks forward to working with the FDA to detect cancer earlier, when it is easier to treat.
The company has not announced when the test will be available to order.
Breakthrough device designation is a regulatory shortcut, not an approval. The FDA still has to review the full safety and effectiveness data before the test can be marketed.
Also read: Half a million heart deaths a year may hinge on one unchecked number
Also read: Millions on blood pressure pills skipped a heart-healthy diet
This article is made and published by Aksel Kryhlmand, who may have used AI in the preparation.